Company intelligence / Profile preview

Xirui Life Science

China

Ownership: Private
Development stage: Commercial

Overview

Xirui Life Science is developing Cytopeutics® umbilical cord mesenchymal stem cells (Neuroncell‑EX), licensed from Malaysia’s Shide Biological/Cytopeutics Sdn Bhd. The product is currently being evaluated in a Phase II–III double-blind randomized controlled trial for acute ischemic stroke. Early reports suggest that patients treated within the first 90 days post-stroke may have up to a 90% chance of regaining up to 90% of pre-stroke function, though these are preliminary claims and not yet confirmed by published peer-reviewed data.

Therapeutic areas: Cardiovascular
Modalities: Stem cell therapyCell therapyUmbilical cord mesenchymal stem cells
Industry: Biotech

Partnerships

Cytopeutics Sdn Bhd/Shide Biological (Malaysia)

Beyond the preview

Go deeper on Xirui Life Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xirui Life Science.

Explore the full profile